FORTICAL
LOE Approachingcalcitonin salmon recombinant
NDANASALSPRAY, METERED
Approved
Aug 2005
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 6d ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
FORTICAL is a recombinant calcitonin salmon nasal spray approved in 2005 for osteoporosis management. It is a hormone-based therapy that works by inhibiting osteoclast-mediated bone resorption and increasing bone mineral density. The drug targets postmenopausal women and patients at risk of fracture.
LOE Approaching
As LOE approaches, expect portfolio rebalancing and potential team restructuring; career growth opportunities lie in transition planning and launch of successor therapies.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on FORTICAL offers experience in managing a mature, legacy osteoporosis asset in a competitive market with declining exclusivity. This role provides exposure to lifecycle management, competitive strategy, and payer negotiations as the product approaches loss of exclusivity.
Brand ManagerProduct Manager
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.